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Liver cancer is the second-leading cause of cancer related death worldwide in men after lung
cancer and is continually increasing in incidence. Specifically, cholangiocarcinoma (CCA), or
bile duct carcinoma, is a malignancy originating in the cholangiocytes of the biliary tree. As the
cancer progresses, it impacts many aspects of the patient’s life, making it important for registered
dietitian nutritionists (RDN) to assist the patient through all aspects of the Nutrition Care Process
including nutrition assessment, diagnosis, intervention, monitoring and evaluation, and also
referrals. An understanding of the disease is necessary for the RDN to provide competent
medical nutrition therapy for their liver cancer patients and this can be done utilizing the
Nutrition Care Process.

Definition & Pathophysiology
Adult stem cells are undifferentiated cells with endless replicative potential that can
differentiate into specialized cells with the primary role of sustaining the turnover of
physiological tissue and tissue repair on varying types of injury. Stem cells are associated with
their fast turnover in tissues of the gastrointestinal tract, skin, and bone marrow and are more
prone to malignant transformation. These cells are recognized as a source of cancer due to their
long lifetime and ability to self-renew.
Cells of a developed liver, however, have a gradual turnover period averaging a hepatocyte
life span range of 200 to 300 days (Sia et al., 2017). The body’s largest organ, the liver,
processes and stores nutrients, produces cholesterol, proteins, clotting factors, lipoproteins to
transport cholesterol, bile, and has metabolic functions such as detoxifying carcinogens.
The types of liver cancer are split into hepatocellular carcinoma (HCC) and
cholangiocarcinoma (CCA), which are further divided into subclasses. HCC, or primary liver
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cancer, is the most prevalent form of liver cancer, accounting for 80% of cases. The forms of
CCA are classified based on anatomical location with intrahepatic (iCCA), perihilar (pCCA), and
distal (dCCA). CCA itself is an epithelial cell malignancy in varying locations of the biliary tree.
The most common histological subtype of CCA encountered is adenocarcinoma, or mucusproducing glandular cells of organs. The tumor, node, metastasis (TNM) staging is a
classification system used to identify the extent of the tumor, its size, and degree of growth and
spread. CCA is not commonly diagnosed until after the cancer has metastasized, meaning that
the cancer spreads to nearby organs, such as the liver, lymph nodes, and lungs (Razumilava &
Gores, 2014). The late onset of symptoms causes a poor average survival rate at five years of
12% (World, 2015).

Etiology & Epidemiology
Each year in the United States, approximately 5,000 individuals are diagnosed with CCA
(DeOliveira et al., 2007). Recent years have shown an unexplained global increase in CCA
incidence and mortality. Tumors can occur anywhere along the biliary tree from the peripheral
intrahepatic ducts to the intraduodenal bile duct. Men are affected 1.5 times more than women
(Shaib Y, 2004). Risk of developing liver cancer increases with age, with the majority of cases
diagnosed at age 75 (World, 2015). Cholangiocarcinoma is most prevalent in regions of Eastern
Asia due to liver flukes in raw fish. Liver fluke infection is caused by parasites in the water such
as Opisthorchis viverrini, Clonorchis senisis, and Opisthorchis felineus, that can be transmitted
to humans through the consumption of raw infected fish. Other risk factors include primary
sclerosing cholangitis, biliary stones, chemical carcinogens, alcoholic liver disease, cirrhosis,
viral hepatitis, and diabetes.
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The case of liver cancer that will be presented is my uncle, who we’ll refer to as DB, who
was diagnosed with liver cancer at age 55. He experienced fever, weakness, nausea, and
vomiting, causing him to need help on his farm as the disease progressed. When I was younger,
he would help me plant a large garden at his farm and he would take me for rides on the tractors.
At stage IV and receiving treatments, he now has difficulty walking and extreme fatigue. Farm
Rescue and dozens of members of the community have come out to support him and help with
crops this year.

Nutrition Assessment
The nutrition assessment is the process of collecting and interpreting data related to an
individual’s food and nutrient intake, lifestyle, and medical history. During each stage of the
cancer process, individuals experience the disease differently making it important for the RDN to
provide a complete nutritional assessment of the client’s health. The Malnutrition Universal
Screening Tool (MUST), the Malnutrition Screening Tool (MST), and the Malnutrition
Screening Tool for Cancer Patients are useful within the inpatient setting. The RDN should
assess energy and protein intake, changes in food and fluid/beverage intake, changes in type,
texture, or temperature of food and liquids, use of medical food supplements, food avoidance or
intolerances, medications, alternative medicine, and factors affecting access to food.
Normal, healthy cells in the body that are susceptible to the effects of these lethal
chemotherapeutic agents include those that divide frequently, such as the cells of the bone
marrow (red blood cells, white blood cells, and platelets), the epithelial lining of the
gastrointestinal tract, and the hair follicles. The most common side effects, therefore, are due to
toxicity to these cells and include neutropenia, thrombocytopenia, anemia, diarrhea, mucositis,
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and alopecia. Some chemotherapeutic agents are known to cause cardiotoxicity, neurotoxicity,
and nephrotoxicity (Nelms, 2016). Cancer cachexia, which is experienced by most patients, is
defined as “weight loss, wasting of muscle, loss of appetite, and general debility that can occur
during a chronic disease” (Nelms, 2016). As the cancer and treatments progress, patients may
need assistance preparing and eating foods.
Symptoms typically do not appear until the cancer has advanced and include abdominal
pain and swelling, weight loss, decreased appetite, jaundice, and fever. A common clinical sign
is enlargement of the liver. Patients with cancer may experience hypermetabolism and require a
higher amount of energy to prevent weight loss. The kilocalorie recommendation for individuals
who are slightly hypermetabolic need to gain weight or are anabolic is 30-35 kcal/kg.
Additionally, protein requirements are elevated to support cell growth and healing, often falling
between 1.5 and 2.5 g/kg of ideal body weight (IBW) per day, but greatly vary among patients
(Nelms, 2016).

Nutrition Focused Physical Examination
A nutrition focused physical examination (NFPE) provides an assessment of muscle
and fat stores as well as functional status through assessing vital signs, loss of muscle mass,
loss of subcutaneous fat, presence of pressure ulcers or wounds, grip strength, and localized
or generalized fluid accumulation. Treatment for liver cancer may involve the support of
enteral or parenteral nutrition as it progresses. The symptoms of liver cancer will rapidly
progress, making it important for the RDN to assess the patient for signs and symptoms of
malnutrition or nutrient deficiencies. Conducting frequent NFPE can assist in identifying
nutritional deficiencies or alterations in the patient’s status. A Functional Assessment of
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IADLs and ADLs can be done using the Subjective Global Assessment and handgrip
dynamometry.

Client History
The nutrition assessment includes client history which helps to provide the RDN with
knowledge surrounding patient history, medical/health/family history, use of
complementary/alternative medicine, previous surgeries, and social history. Specifically, for
CCA, determine if the patient has a history of cirrhosis, alcoholic liver disease, viral
hepatitis, diabetes, or primary sclerosing cholangitis. Liver cancer not only affects the patient
but their family and friends as well. Especially as the cancer progresses, it will be important
for the patient to have a network in place to help and support them throughout the process.
DB grew up in a rural agricultural region and helped on the farm from a very young age.
He eventually took over the family farm and has devoted his life to it. He lives alone and
does not have issues with socioeconomic status or food security. After 6 months of fevers,
abdominal pain, nausea, vomiting, decreased appetite, weight loss and multiple doctor visits,
it was finally concluded that he had liver cancer. Like most farmers, he did have some
previous injuries on the farm, including injuries to the knee and surviving a tornado, but no
related medical history to the CCA. After one of his flights back after treatment, he ended up
in the emergency room with a blood clot in his lung. An additional side effect includes an
infected spleen during chemo treatment. For support, DB’s sister has been educating herself
about liver cancer to provide better care for him and to help him out with doctor visits.
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Food and Nutrition Related History
Since cancer and its treatments greatly impact all aspects of a patient’s life, it is
important that the RDN asks the patient about their appetite, gastrointestinal function, and
any other symptoms that may interfere with their ability to maintain adequate nutritional
intake through their diet. When meeting with the patient, an RDN should ask about any
avoidance of food or complications with eating because it can lead to inadequate intake,
especially if frequent. Patients with liver cancer may experience cancer cachexia, nausea,
vomiting, anorexia, unintended weight loss, jaundice, upper abdominal pain and swelling,
weakness, and fatigue. The diet history will document the patient’s intake patterns, food
preferences, cultural values, their use of supplements, and alcohol intake. Collecting
information on patients is important because not all patients with liver cancer are affected by
the same foods and some patients may find that consuming small, frequent meals suits their
situation. DB no longer tolerates foods high in sugar but will still try to eat items like candy
bars and finds that they do not taste good anymore.
Concerning previous nutrition education and counseling, the RDN should evaluate
whether the patient recalls previously learned nutrition education and what the patient has
tried. Establish any food allergies or intolerances to determine if the patient has access to
resources to purchase and prepare food. To collect additional data, the RDN can suggest a
food record or food diary, 24-hour food recall, or a food frequency.
DB has chosen to be part of experimental trials and travels down to a cancer center in
Arizona, which means that he has to stay in hotels for weeks at a time. During these times, he
has limited food options including restaurants, fast food, a Target within walking distance,
and a mini fridge to store foods. When he is at home, DB typically does not cook for himself
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but will microwave frozen dinners. He has experienced dramatic changes in food tolerance
throughout the progression of cancer and the treatment period, which interferes with his
appetite and causes him to skip meals. He stated that some of his favorite foods to eat lately
have been potatoes, oatmeal, and pasta dishes. DB also has struggled with drinking water and
says it started tasting gross around the time symptoms started presenting. When he does eat,
it is large amounts. I remember handing him a pack of crackers and he ate the entire thing
and asked if I had any more food. He is thankful that he still has the farm to keep him active
whether he’s getting calls all day down in Arizona or running equipment in the fields for an
hour at a time. This has also kept his strength up because he would rather lay in bed all day
than have to get up and walk, but with the farm he’s moving frequently.

Anthropometrics
The measurement of body size, weight, and body composition are anthropometric data
obtained during the nutrition assessment that can be used to identify goals for nutrition
intervention. Monitoring for deviations from the usual body weight (UBW) is used to help
identify nutritional risk and disease complications. What commonly occurs with liver cancer
is unintentional weight loss, cancer cachexia, and fatigue which can be objectively measured
in the anthropometrics. The RDN will evaluate the patient’s height, current weight, highest
weight, UBW, change in weight, and BMI. The following classify the percentage of weight
loss in terms of malnutrition:
Moderate weight loss
-

1-2% in 1 week

-

5% in 1 month
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7.5% in 3 months

-

10% in 6 months
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Severe weight loss
-

>2% over 1 week

-

>5% over 1 month

-

>7.5% over 3 months

These percentage classifications can be used to interpret the significance of weight loss.
The BMI of a healthy individual would range from 19-24 kg/m2. I always remember DB
being within a healthy weight range. DB’s height is 6’5”, current weight 200 pounds, BMI
23.7 kg/m2, UBW 225, change in body weight 8% in 3 months. About 4 months ago he did
drop to 180 pounds but has gained weight since and stated that his weight has fluctuated a lot
recently. Healthy body weight for an individual of this height is 187-229lbs. He is within
healthy body weight range but has lost a significant amount of muscle. Now, DB is visibly
experiencing cachexia, extreme fatigue, and is concerned about how weak he has become. I
remember driving him home after a flight while he complained, “I have no butt left and it
hurts to sit for long periods of time.”

Biochemical Data, Medical Tests, and Procedures
Biochemical data for the nutrition assessment includes laboratory data, tumor markers,
scans, tests, and medications. Tumor markers can be utilized to identify presence of disease
or response to therapy. The biochemical data available for a patient must be interpreted in the
context of the individual patient’s disease state. There is no blood test available to diagnose
CCA. Elevated liver function markers such as bilirubin (normal range 0.1-1.2 mg/dL),
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alkaline phosphatase (44-147 IU), and aminotransferase (<50 U/L) indicate an obstruction,
but not necessarily malignancy (Alsaleh et al., 2018). Commonly used serum tumor markers
for CCA are carbohydrate antigen (CA)19-9 (<100 U/mL), CA-125 (<46 U/mL), alphafetoprotein (10-20 ng/mL), and carcinoembryonic antigen (CEA) (<2.5 ng/mL). These
markers are used in conjunction with other diagnostic tools because of their poor ability to
diagnose.
Additional methods of detection include high resolution imaging, computed tomography,
and magnetic resonance imaging (MRI), which provide more accuracy for detecting CCA
than conducting an ultrasound (Alsaleh et al., 2018). Surgical resection is the only curative
therapy for CCA. The majority of CCA cases are identified late, not allowing for surgical
intervention. The treatment guidelines recommend a combination of Gemcitabine and
Cisplatin chemotherapy for cases in which surgery is not an option (Alsaleh et al., 2018.)
Individuals with liver cancer may be at an increased risk of specific vitamin and mineral
deficiencies. Those with liver cancer were found to be deficient in vitamin D and studies
have suggested a relationship between vitamin D status and the development of cancer.
(Schütte et al., 2016). The use of Cisplatin may require supplementation of magnesium,
calcium, and potassium. Fat malabsorption occurs in this population due to decreased
secretion of bile salts, which may cause a patient to become deficient in fat soluble vitamins
A (men-900 ug/RAE., women-700 ug/RAE), D (12- 20 ng/mL), E (15 mg), and K (0.2-3.2
ng/mL). Minerals such as zinc (men-11 mg, women-8 mg), manganese (4–15 μg/L), and
copper (70-140 μg/dL) are excreted in the bile. If the bile is not secreted adequately, these
minerals may accumulate in the blood. Monitor serum levels of these nutrients to determine
if specific foods should be added or avoided, if supplements are necessary, or if changes in
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medications need to be considered. DB has been supplementing iron, magnesium, omega-3,
thiamin, folate, vitamin B-12, vitamin C, and vitamin E.
The common medications prescribed for liver cancer and chemotherapy treatments have
side effects that impact the patient’s daily living and ability to consume food.
o Cisplatin is an alkylating agent chemotherapy that alters DNA structure by
misreading DNA code, initiating breaks in the DNA molecule, cross-linking DNA
strands. This can cause bone marrow suppression, nausea, vomiting, stomatitis,
alopecia, gonadal suppression, and renal toxicity.
o Gemcitabine (Gemzar) is a cytotoxic chemotherapy that has numerous side effects
including fever, headache, sore mouth, difficulty moving and swallowing, nausea,
vomiting, sore throat, lack of appetite, and low white blood cell count.
In the experimental trials, DB is receiving treatment from a combination of Cisplatin and
Gemcitabine. He had a port placed in the right side of his chest to prepare him for treatment.
DB said he has experienced neuropathy, very low white blood cell count, and his vision is
worsening due to the Cisplatin. This has been upsetting for him because he is concerned with
having lasting side effects.

Nutrition Diagnosis
Nutrition diagnoses will vary based on the primary tumor site, extent of tumor burden,
and treatment modality and individual nutrition assessment. Possible diagnoses include increased
nutrient needs, inadequate oral intake, malnutrition, inadequate fluid intake, altered GI function,
swallowing and/or biting/chewing difficulty, unintended weight loss, impaired ability to prepare
foods/meals, or malnutrition. Possible PES statements include the following:
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o Inadequate oral intake related to lack of appetite as evidenced by poor appetite
and 2% weight loss over 2 weeks.
o Increased fluid needs related to sweat loss from fever as evidenced by
dehydration and poor skin turgor.
o Severe malnutrition related to loss of appetite as evidenced by unintentional
weight loss of 8% in 3 months and severe depletion of muscle and fat mass.
o Food-medication interaction related to use of Gemcitabine and Cisplatin as
evidenced by dry mouth, diarrhea, and loss of appetite.
o Impaired ability to prepare foods/meals related to cancer treatments as
evidenced by reduced mobility, fatigue, and decreased intake of less than 75%
of estimated energy needs.

Possible Interventions
Nutrition intervention occurs in two stages a planning stage and an implementation stage.
There are four categories to consider during planning and implementation of the nutrition
intervention: nutrition education, nutrition counseling, food and nutrient delivery, and
coordination of care.
For DB’s case of CCA, I would choose all four of these. Possible interventions for
patients with liver cancer include:
o Cancer induced nausea and vomiting (CINV) is often experienced by patients
undergoing chemotherapy which may originate from radiation, anticipatory,
and chemotherapy. Patients are often prescribed antiemetics to control the
nausea and vomiting which should be taken 30-45 minutes before a meal.
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o For emesis, eat a small, low-fat meal in the morning of the treatment and
avoid fried, greasy, and favorite foods for several days following.
o Early satiety due to delayed gastric emptying is improved with small, frequent
meals that are nutrient dense. Beverages should also be nutrient dense and
consumed prior to or between meals to avoid the feeling of fullness.
o Follow guidelines for the prevention and treatment of mouth sores associated
with mucositis. Additionally, a patient may eat soft, nonfibrous, nonacidic
foods, and avoid hot foods. High-calorie, high-protein shakes or nutritional
supplements may be beneficial.
o Patients with diarrhea should be encouraged to drink small amounts of fluid
frequently, avoid large amounts of fruit juice, and use antidiarrheal
medications as prescribed.
o Chemotherapeutic agents, specifically cisplatin, cause dysgeusia. Individuals
may prefer use plastic utensils instead of metal ones to avoid a metallic taste
in their mouth. Meats are often not tolerated and high-protein foods are
encouraged.
o Patients lacking taste should be encouraged to use more highly spiced and
flavorful foods.
o In those experiencing xerostomia, sugar-free gum may increase the flow of
saliva in the mouth.
o Home delivered meals through a delivery system such as Meals on Wheels.
o Motivational interviewing to assist with shifts in lifestyle.
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o Exercise to help increase appetite in those with anorexia. At least 30 minutes
of physical activity a day is recommended, but any amount during treatment is
beneficial.
Prior to DB starting the experimental trials he drank Essiac Tea because a friend had
researched and heard that this tea would help with appetite for cancer patients. He still makes
sure to drink this tea at least once a day. His weight fluctuates within a range of 5-10 pounds, but
has not significantly changed in recent months.

Nutrition Monitoring & Evaluation.
The approach to monitoring and evaluating a patient should be based on the nutrition
diagnoses and interventions implemented. Nutrition intervention domains will be reassessed for
effectiveness and revised as appropriate. Typically, weight and weight change will be measured,
caloric and protein intakes determined, and components of the NFPE are reassessed for any
changes or risk of malnutrition. The RDN will determine their tolerance to the diet and identify
any changes in symptoms. At the follow-up visit, food and nutrition-related education can be
evaluated to determine how the patient is receiving the information and if they have applied any
concepts. Patients who have completed treatment for a malignancy may modify goals including
eat mostly plant-based foods, which are low in energy density, remain physically active, and
maintain a healthy weight.
Monitoring DB is unique due to the experimental trial and COVID precautions. Being
that he is immunocompromised and has already experienced a blood clot from flying, traveling
for treatment has been risky, especially with the threat of COVID-19. He communicates through
telehealth with members of his care team that are out-of-state. He is fortunate to be financially
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stable because the experimental trials are not covered by insurance. He has not met with a
dietitian because his intake has been adequate recently but plans to if his health begins to decline.

Prevention & Conclusion
The American Institute for Cancer Research Guidelines for Cancer Prevention has
established prevention measures for clinicians to recommend to their patients include: being at
the lower end of the healthy BMI range, getting 30 minutes of physical activity per day, avoiding
sugary drinks, limiting the intake of energy dense foods and red or processed meats, eating a
variety of fruits, vegetables, whole grains, and legumes, and limiting alcoholic beverages. Strong
evidence suggests that drinking 1-2 cups of coffee each day decreases the risk of liver cancer
(World, 2015). Additionally, the intake of alcoholic beverages to 2 a day for men and 1 for
women is shown to reduce the risk of liver diseases and liver cancer. Of individuals with chronic
hepatitis C, 1-4% develop liver cancer (World, 2015). The RDN has a crucial role of handling
dietary choices and nutritional status of a patient throughout the treatment of cancer because
many patients are at increased nutritional risk.
I found researching this type of cancer and the NCP to very interesting, especially
because DB is still in the process of treatment. This project also helped me to learn more about
how cancer overall is approached from a dietetic standpoint since the treatment of liver cancer
does not significantly vary from the treatment of other types of cancer.
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